Evidence map›Paper›PMID 22226271›Full record

ArticleJournal of diabetes science and technology2011

Activation of polymorphonuclear leukocytes by candidate biomaterials for an implantable glucose sensor.

Andrey Sokolov, Bernt Christian Hellerud, John D Lambris, Erik A Johannessen, Tom Eirik Mollnes

Abstract read
In one paragraph

Article in Journal of diabetes science and technology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Progress and Trends in Complement Therapeutics.Advances in experimental medicine and biology · 2013
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Andrey SokolovInstitute of Immunology, University of Oslo and Oslo University Hospital Rikshospitalet, Oslo, Norway. andrey.sokolov@medisin.uio.no
Bernt Christian Hellerud
John D Lambris
Erik A Johannessen
Tom Eirik Mollnes

Funding

Role of complement in kidney disorders: from hemodialysis to transportationP01AI068730 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI LAMBRIS, JOHN D · 2007 to 2018
$16.0M
STRUCTURAL-FUNCTIONAL ANALYSIS OF COMPSTATINR01GM062134 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI LAMBRIS, JOHN D · 2001 to 2010
$2.5M
NIAID NIH HHS AI068730NIGMS NIH HHS GM062134
6 · The paper itself

Abstract

backgroundContinuous monitoring of glucose by implantable microfabricated devices offers key advantages over current transcutaneous glucose sensors that limit usability due to their obtrusive nature and risk of infection. A successful sensory implant should be biocompatible and retain long-lasting function. Polymorphonuclear leukocytes (PMN) play a key role in the inflammatory system by releasing enzymes, cytokines, and reactive oxygen species, typically as a response to complement activation. The aim of this study was to perform an in vitro analysis of PMN activation as a marker for biocompatibility of materials and to evaluate the role of complement in the activation of PMN.

methodsFifteen candidate materials of an implantable glucose sensor were incubated in lepirudin-anticoagulated whole blood. The cluster of differentiation molecule 11b (CD11b) expression on PMN was analyzed with flow cytometry and the myeloperoxidase (MPO) concentration in plasma was analyzed with enzyme-linked immunosorbent assay. Complement activation was prevented by the C3 inhibitor compstatin or the C5 inhibitor eculizumab.

resultsThree of the biomaterials (cellulose ester, polyamide reverse osmosis membrane, and polyamide thin film membrane), all belonging to the membrane group, induced a substantial and significant increase in CD11b expression and MPO release. The changes were virtually identical for these two markers. Inhibition of complement with compstatin or eculizumab reduced the CD11b expression and MPO release dose dependently and in most cases back to baseline. The other 12 materials did not induce significant PMN activation.

conclusionThree of the 15 candidate materials triggered PMN activation in a complement-dependent manner and should therefore be avoided for implementation in implantable microsensors.

Indexed as

Materials TestingBiocompatible MaterialsBlood GlucoseCell SeparationEnzyme-Linked Immunosorbent AssayFlow CytometryHumansNeutrophilsProstheses and ImplantsBiocompatible MaterialsBlood Glucose

Identifiers

PMID22226271
PMCPMC3262720

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.